Publications

  1. Hubbard JM, Cohen HJ, Muss HB. Incorporating Biomarkers Into Cancer and Aging Research. J Clin Oncol. 2014 Aug 20; 32(24):2611-6. Epub 2014 Jul 28.
    View PubMed
  2. Hubbard JM, Grothey AF, McWilliams RR, Buckner JC, Sloan JA. Physician Perspective on Incorporation of Oncology Patient Quality-of-Life, Fatigue, and Pain Assessment Into Clinical Practice. J Oncol Pract. 2014 Jul; 10(4):248-53. Epub 2014 Mar 25.
    View PubMed
  3. Gonsalves WI, Mahoney MR, Sargent DJ, Nelson GD, Alberts SR, Sinicrope FA, Goldberg RM, Limburg PJ, Thibodeau SN, Grothey A, Hubbard JM, Chan E, Nair S, Berenberg JL, McWilliams RR, Alliance for Clinical Trials in Oncology. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst. 2014 Jul; 106(7). Epub 2014 Jun 12.
    View PubMed
  4. Sridharan M, Hubbard J, Grothey A. Colorectal Cancer: How Emerging Molecular Understanding Affects Treatment Decisions Oncology. 2014 Feb 15. [Epub ahead of print]
  5. Hubbard JM, Grothey A. Adolescent and young adult colorectal cancer. J Natl Compr Canc Netw. 2013 Oct 1; 11(10):1219-25.
    View PubMed
  6. Hubbard JM, Alberts SR. Alternate dosing of cetuximab for patients with metastatic colorectal cancer. Gastrointest Cancer Res. 2013 Mar; 6(2):47-55.
    View PubMed
  7. Hubbard J, Thomas DM, Yothers G, Green E, Blanke C, O'Connell MJ, Labianca R, Shi Q, Bleyer A, de Gramont, Sargent D. Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: findings from the Adjuvant Colon Cancer Endpoints data set. J Clin Oncol. 2012 Jul 1; 30(19):2334-9. Epub 2012 May 21
    View PubMed
  8. Lewis M, Hubbard J. Treatment of liver-limited disease from colorectal cancer. Journal of Interventional Oncology. March 2012; 2(1):15-24.
  9. Hubbard J, Erlichman C, Toft DO, Qin R, Stensgard BA, Felten S, Ten Eyck C, Batzel G, Ivy SP, Haluska P. Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors. Invest New Drugs. 2011 Jun; 29(3):473-80. Epub 2010 Jan 15.
    View PubMed
  10. Hubbard JM, Grothey A, Sargent DJ. Systemic therapy for elderly patients with gastrointestinal cancer. Clin Med Insights Oncol. 2011; 5:89-99. Epub 2011 Apr 25.
    View PubMed
  11. Lewis MA, Hubbard J. Multimodal liver-directed management of neuroendocrine hepatic metastases. Int J Hepatol. 2011; 2011:452343. Epub 2011 Oct 29.
    View PubMed
  12. Hubbard J, Grothey A. Reduced chemotherapy duration: A good idea? Current Colorectal Cancer Reports. 2011; 7(3):241-5.
  13. Hubbard J, Grothey A. Antiangiogenesis agents in colorectal cancer. Curr Opin Oncol. 2010 Jul; 22(4):374-80.
    View PubMed
  14. Hubbard JM, Alberts SR. Treatment of liver-limited metastatic colorectal cancer. Cancer J. 2010 May-Jun; 16(3):235-40.
    View PubMed
  15. de Gramont A, Hubbard J, Shi Q, O'Connell MJ, Buyse M, Benedetti J, Bot B, O'Callaghan C, Yothers G, Goldberg RM, Blanke CD, Benson A, Deng Q, Alberts SR, Andre T, Wolmark N, Grothey A, Sargent D. Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. J Clin Oncol. 2010 Jan 20; 28(3):460-5. Epub 2009 Dec 14.
    View PubMed
  16. Hubbard J, Grothey A. Strategies for managing chemotherapy-induced sensory neuropathy. Current Colorectal Cancer Reports. 2010; 6(3):126-32.
  17. Hubbard J, Sargent D. Evidence for Cure by Adjuvant Chemotherapy in Colorectal Cancer Review. American Journal of Hematology/Oncology. 2009; 8(9):419-24.
  18. Turja J, Grothey A. Individualizing therapy for metastatic colorectal cancer. Oncology (Williston Park). 2008 Nov 30; 22(13):1479-81.
    View PubMed